Leveraging metformin to combat hepatocellular carcinoma: its therapeutic promise against hepatitis viral infections

Abstract

Hepatocellular carcinoma (HCC) is categorized among the most common primary malignant liver cancer and a primary global cause of death from cancer. HCC tends to affect males 2-4 times more than females in many nations. The main factors that raise the incidence of HCC are chronic liver diseases, hepatotropic viruses like hepatitis B (HBV) and C (HCV), non-alcoholic fatty liver disease, exposure to toxins like aflatoxin, and non-alcoholic steatohepatitis (NASH). Among these, hepatitis B and C are the most prevalent causes of chronic hepatitis globally. Metformin, which is made from a naturally occurring compound called galegine, derived from the plant Galega officinalis (G. officinalis), has been found to exhibit antitumor effects in a wide range of malignancies, including HCC. In fact, compared to patients on sulphonylureas or insulin, studies have demonstrated that metformin treatment significantly lowers the risk of HCC in patients with chronic liver disease. This article will first describe the molecular mechanism of hepatitis B and C viruses in the development of HCC. Then, we will provide detailed explanations about metformin, followed by a discussion of the association between metformin and hepatocellular carcinoma caused by the viruses mentioned above.

Keywords

Hepatocellular carcinoma / HCC / hepatitis B virus / hepatitis C virus / metformin

References

[1] Bruix J,Mazzaferro V.Hepatocellular carcinoma: clinical frontiers and perspectives.Gut2014;63:844-55 PMCID:PMC4337888

[2] Mardpour S,Mardpour S.Extracellular vesicles derived from human embryonic stem cell-MSCs ameliorate cirrhosis in thioacetamide-induced chronic liver injury.J Cell Physiol2018;233:9330-44

[3] McGlynn KA,El-Serag HB.Epidemiology of hepatocellular carcinoma.Hepatology2021;73 Suppl 1:4-13 PMCID:PMC7577946

[4] Nahand JS,Hamblin MR.Circular RNAs: new epigenetic signatures in viral infections.Front Microbiol2020;11:1853 PMCID:PMC7412987

[5] Yang JD.Hepatocellular carcinoma: a global view.Nat Rev Gastroenterol Hepatol2010;7:448-58 PMCID:PMC3926946

[6] Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.Hepatology2011;53:1020-2 PMCID:PMC3084991

[7] Khadempour-Arani H,Mehri-Ghahfarrokhi A.Identifying genotype profile of chronic hepatitis C infection in Southwest Iran.J Res Med Sci2020;25:85 PMCID:PMC7698378

[8] Gao C,Zhao HC,Yao SK.Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a cross-sectional case-control study from Chinese patients with HBV infection.Hepatobiliary Pancreat Dis Int2013;12:385-93

[9] Puoti M,Soriano V.Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome.AIDS2004;18:2285-93

[10] Saito T,Yuki K.Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells.PLoS One2013;8:e70010 PMCID:PMC3726625

[11] Choi YK.Metabolic roles of AMPK and metformin in cancer cells.Mol Cells2013;36:279-87 PMCID:PMC3887985

[12] Cunha V,Rocha R,Lins-Kusterer L.Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review.Ann Hepatol2020;19:232-7

[13] Donadon V,Mas MD,Zanette G.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.Liver Int2010;30:750-8

[14] Saber S,El-Ahwany E.Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis.Cancer Chemother Pharmacol2020;85:331-43

[15] Akamatsu N,Cucchetti A.Surgery and hepatocellular carcinoma.Liver Cancer2016;6:44-50 PMCID:PMC5159722

[16] Idée JM.Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.Crit Rev Oncol Hematol2013;88:530-49

[17] Li H,Duan M.Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety.Medicine2019;98:e15314 PMCID:PMC6571239

[18] Garrido A.Cirrhosis: a questioned risk factor for hepatocellular carcinoma.Trends Cancer2021;7:29-36

[19] Lai CL.Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.Hepatology2013;57:399-408

[20] Chang PY,Chang WC.The effect of propranolol on the prognosis of hepatocellular carcinoma: a nationwide population-based study.PLoS One2019;14:e0216828 PMCID:PMC6534323

[21] Degasperi E,Lampertico P.Towards a functional cure for hepatitis B virus: a 2022 update on new antiviral strategies.Viruses2022;14:2404 PMCID:PMC9699048

[22] Kodali S.Potent suppression of hepatitis B virus and hepatocellular carcinoma: how long is good enough?.Hepatobiliary Surg Nutr2018;7:212-3 PMCID:PMC6036064

[23] Yoon SK.Molecular mechanism of hepatocellular carcinoma.Hepatoma Res2018;4:42

[24] Wang G.HBV genomic integration and hepatocellular carcinoma.Adv Gut Microbiome Res2022;2022:2140886

[25] Nevola R,Rosato V.HBV infection and host interactions: the role in viral persistence and oncogenesis.Int J Mol Sci2023;24:7651 PMCID:PMC10145402

[26] Wang LH.Correction: salvador-warts-hippo pathway regulates sensory organ development via caspase-dependent nonapoptotic signaling.Cell Death Dis2019;10:797 PMCID:PMC6805860

[27] Cheng Y,Lu Y.The biology of YAP in programmed cell death.Biomark Res2022;10:34 PMCID:PMC9128211

[28] Wu Y,Zhang H.Hepatitis B virus X protein mediates yes-associated protein 1 upregulation in hepatocellular carcinoma.Oncol Lett2016;12:1971-4 PMCID:PMC4998520

[29] Wang J,Weng W.Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer.Hepatology2013;58:1011-20

[30] Zhang T,You X.Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.Hepatology2012;56:2051-9

[31] Oda C,Shibata O.HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma.Biochem Biophys Rep2022;32:101352 PMCID:PMC9490549

[32] Li L,Shi Z,Zhou LY.The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC.Oncol Lett2016;12:3045-50 PMCID:PMC5103898

[33] Younis NS,Saber S.Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.Sci Rep2019;9:19095 PMCID:PMC6911098

[34] Marra M,Lombardi A.Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.J Transl Med2011;9:171 PMCID:PMC3213217

[35] Méndez-Sánchez N,Zamora-Valdés D.Sorafenib, a systemic therapy for hepatocellular carcinoma.Ann Hepatol2008;7:46-51

[36] Tu W,Tian D.Hepatitis B virus X protein induces SATB1 expression through activation of ERK and p38MAPK pathways to suppress anoikis.Dig Dis Sci2019;64:3203-14

[37] Shan C,Zhang S.Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2.Cell Res2010;20:563-75

[38] Liao B,Liang H.Regulation of ERK and AKT pathways by hepatitis B virus X protein via the Notch1 pathway in hepatocellular carcinoma.Int J Oncol2017;51:1449-59 PMCID:PMC5643068

[39] Orzechowska M,Bednarek AK.Functional gene expression differentiation of the notch signaling pathway in female reproductive tract tissues-a comprehensive review with analysis.Front Cell Dev Biol2020;8:592616 PMCID:PMC7770115

[40] Amata I,Pons M.Phosphorylation of unique domains of Src family kinases.Front Genet2014;5:181 PMCID:PMC4075076

[41] Belli S,Servetto A,Formisano L.c-Src and EGFR inhibition in molecular cancer therapy: what else can we improve?.Cancers2020;12:1489 PMCID:PMC7352780

[42] Yang J,Liu L,Qian Q.c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway.Life Sci2021;264:118711

[43] Yang J,Berx G.Guidelines and definitions for research on epithelial-mesenchymal transition.Nat Rev Mol Cell Biol2020;21:341-52

[44] Yang SZ,Zhang Y.HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line.Biochem Biophys Res Commun2009;382:555-60

[45] Long HZ,Zhou ZW,Wen DD.PI3K/AKT signal pathway: a target of natural products in the prevention and treatment of alzheimer’s disease and parkinson’s disease.Front Pharmacol2021;12:648636 PMCID:PMC8082498

[46] Xu W,Lu N.A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition.Cell Adh Migr2015;9:317-24 PMCID:PMC4594353

[47] Wang Z,Hao G.Aberrant expression of PI3K/AKT signaling is involved in apoptosis resistance of hepatocellular carcinoma.Open Life Sci2021;16:1037-44 PMCID:PMC8477673

[48] Wang HY,Liang HF.HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK/ERK and PI3K/Akt pathways.Int J Mol Sci2014;15:3507-18 PMCID:PMC3975350

[49] Xiang K.Role of the PI3K-AKT-mTOR pathway in hepatitis B virus infection and replication.Mol Med Rep2018;17:4713-9

[50] Zhu M,Li W.HBx induced AFP receptor expressed to activate PI3K/AKT signal to promote expression of Src in liver cells and hepatoma cells.BMC Cancer2015;15:362 PMCID:PMC4427932

[51] Rawat S.The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival.J Virol2015;89:999-1012 PMCID:PMC4300660

[52] Shokri S,Taherkhani R,Jalalian FA.Complexity on modulation of NF-κB pathways by hepatitis B and C: a double-edged sword in hepatocarcinogenesis.J Cell Physiol2019;234:14734-42

[53] You H,Zhang F.Regulation of pattern-recognition receptor signaling by HBX during hepatitis B virus infection.Front Immunol2022;13:829923 PMCID:PMC8891514

[54] Budhu A.The role of cytokines in hepatocellular carcinoma.J Leukoc Biol2006;80:1197-213

[55] Quétier I,Duriez M.Hepatitis B virus HBx protein impairs liver regeneration through enhanced expression of IL-6 in transgenic mice.J Hepatol2013;59:285-91

[56] Wang Y,Yang G.Hepatitis B e antigen inhibits NF-κB activity by interrupting K63-linked ubiquitination of NEMO.J Virol2019;93:e00667-18 PMCID:PMC6321907

[57] Cho IR,Koh SS.Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor.Int J Mol Med2012;29:581-6 PMCID:PMC3577137

[58] Yang Y,Han Q,Tian Z.Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma.Cancer Biol Ther2016;17:449-56 PMCID:PMC4910934

[59] Azbazdar Y,Erdal E.Regulation of wnt signaling pathways at the plasma membrane and their misregulation in cancer.Front Cell Dev Biol2021;9:631623 PMCID:PMC7873896

[60] Mahmoudvand S,Taherkhani R.Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma.World J Gastroenterol2019;25:42-58 PMCID:PMC6328967

[61] Nuñez F,Cruzat F,De Ferrari GV.Wnt/β-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells.PLoS One2011;6:e18562 PMCID:PMC3071840

[62] Zheng BY,Huang XY.HBx promotes the proliferative ability of HL-7702 cells via the COX-2/Wnt/β-catenin pathway.Mol Med Rep2018;17:8432-8

[63] Srisuttee R,Kim SJ.Hepatitis B virus X (HBX) protein upregulates β-catenin in a human hepatic cell line by sequestering SIRT1 deacetylase.Oncol Rep2012;28:276-82

[64] Cha MY,Park YM.Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells.Hepatology2004;39:1683-93

[65] Prud’homme GJ.Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations.Lab Invest2007;87:1077-91

[66] Chen J,Su X.Immunomodulatory TGF-β signaling in hepatocellular carcinoma.Trends Mol Med2019;25:1010-23

[67] Liu Y,Ma H.Hepatitis B virus X protein amplifies TGF-β promotion on HCC motility through down-regulating PPM1a.Oncotarget2016;7:33125-35 PMCID:PMC5078080

[68] Dong KS,Yang G.TGF-β1 accelerates the hepatitis B virus X-induced malignant transformation of hepatic progenitor cells by upregulating miR-199a-3p.Oncogene2020;39:1807-20 PMCID:PMC7033045

[69] Lim HY,Yoon H.Tumor suppressor p53 inhibits hepatitis B virus replication by downregulating HBx via E6AP-mediated proteasomal degradation in human hepatocellular carcinoma cell lines.Viruses2022;14:2313 PMCID:PMC9609658

[70] Yang Y,Li Z,Lei Y.Identification of novel characteristics in TP53-mutant hepatocellular carcinoma using bioinformatics.Front Genet2022;13:874805 PMCID:PMC9149291

[71] Chan C,Wang J.Global re-wiring of p53 transcription regulation by the hepatitis B virus X protein.Mol Oncol2016;10:1183-95 PMCID:PMC5423203

[72] Lacal I.Epigenetic inheritance: concepts, mechanisms and perspectives.Front Mol Neurosci2018;11:292 PMCID:PMC6172332

[73] Tian Y,Song J,Ni B.Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis.Mol Cell Biol2013;33:2810-6 PMCID:PMC3719687

[74] Lee SM,Bae JB.HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators.Proc Natl Acad Sci USA2014;111:9555-60 PMCID:PMC4084425

[75] Jiang Y,Zhao H.The mechanisms of HBV-induced hepatocellular carcinoma.J Hepatocell Carcinoma2021;8:435-50 PMCID:PMC8147889

[76] Mahmoudvand S.Effect of lactate on epigenetic regulation in the development of hepatitis B virus-related hepatocellular carcinoma.J Clin Transl Hepatol2022;10:786-7 PMCID:PMC9547259

[77] Kesheh MM,Shokri S.Long noncoding RNAs in respiratory viruses: a review.Rev Med Virol2022;32:e2275 PMCID:PMC8420315

[78] Lin X,Feng B.Targeting long non-coding RNAs in hepatocellular carcinoma: progress and prospects.Front Oncol2021;11:670838 PMCID:PMC8267409

[79] Hu JJ,Zhang SD.HBx-upregulated lncRNA UCA1 promotes cell growth and tumorigenesis by recruiting EZH2 and repressing p27Kip1/CDK2 signaling.Sci Rep2016;6:23521 PMCID:PMC4806364

[80] Salerno D,Alfano V.Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.Gut2020;69:2016-24 PMCID:PMC7569396

[81] Samudh N,Arbuthnot P,Ely A.Diversity of dysregulated long non-coding RNAs in HBV-related hepatocellular carcinoma.Front Immunol2022;13:834650 PMCID:PMC8831247

[82] Peng Y.The role of MicroRNAs in human cancer.Signal Transduct Target Ther2016;1:15004 PMCID:PMC5661652

[83] Sartorius K,An P.The multiple roles of hepatitis B virus X protein (HBx) dysregulated MicroRNA in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and immune pathways.Viruses2020;12:746 PMCID:PMC7412373

[84] Tian Y,Gong X.HBx promotes cell proliferation by disturbing the cross-talk between miR-181a and PTEN.Sci Rep2017;7:40089 PMCID:PMC5215388

[85] Zhang Q,Yao L.miR-3928v is induced by HBx via NF-κB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3.J Exp Clin Cancer Res2018;37:14 PMCID:PMC5789631

[86] Yang S,Li X.New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies.Am J Cancer Res2019;9:1329-53 PMCID:PMC6682711

[87] Liu L,He XX.The role of autophagy in hepatocellular carcinoma: friend or foe.Oncotarget2017;8:57707-22 PMCID:PMC5593678

[88] Cui J,Lim LHK.The role of autophagy in liver cancer: crosstalk in signaling pathways and potential therapeutic targets.Pharmaceuticals2020;13:432 PMCID:PMC7760785

[89] Wang P,Wang ZW.HBx induces HepG-2 cells autophagy through PI3K/Akt-mTOR pathway.Mol Cell Biochem2013;372:161-8

[90] Son J,Lee JS,Chun E.Hepatitis B virus X protein promotes liver cancer progression through autophagy induction in response to TLR4 stimulation.Immune Netw2021;21:e37 PMCID:PMC8568915

[91] Luo MX,Chan MT.Autophagy mediates HBx-Induced nuclear factor-κB activation and release of IL-6, IL-8, and CXCL2 in hepatocytes.J Cell Physiol2015;230:2382-9

[92] Jeon JS,Ban K.Regulation of the intracellular ROS level is critical for the antiproliferative effect of quercetin in the hepatocellular carcinoma cell line HepG2.Nutr Cancer2019;71:861-9 PMCID:PMC7513677

[93] Nour H,Samir D.A study of the relationship between oxidative stress and risk of developing hepatocellular carcinoma in people with hepatitis B infection; A systematic review study.Asian Pac J Cancer Biol2021;6:316-20

[94] Waris G.Reactive oxygen species: role in the development of cancer and various chronic conditions.J Carcinog2006;5:14 PMCID:PMC1479806

[95] Ha HL.HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway.World J Gastroenterol2010;16:4932-7 PMCID:PMC2957601

[96] Lim W,Cho H.HBx targeting to mitochondria and ROS generation are necessary but insufficient for HBV-induced cyclooxygenase-2 expression.J Mol Med2010;88:359-69

[97] Suhail M,Kamal MA.Role of hepatitis C virus in hepatocellular carcinoma and neurological disorders: an overview.Front Oncol2022;12:913231 PMCID:PMC9372299

[98] Aman W,Shiha G.Current status and future directions in the management of chronic hepatitis C.Virol J2012;9:57 PMCID:PMC3325870

[99] Sharma SD.Hepatitis C virus: molecular biology & current therapeutic options.Ind J Med Res2010;131:17-34

[100] Vranjkovic A,Kaka S,Cooper CL.Direct-acting antiviral treatment of HCV infection does not resolve the dysfunction of circulating CD8⁺ T-cells in advanced liver disease.Front Immunol2019;10:1926 PMCID:PMC6700371

[101] Heredia-Torres TG,Lozano-Sepúlveda SA.Unraveling the molecular mechanisms involved in HCV-induced carcinogenesis.Viruses2022;14:2762 PMCID:PMC9786602

[102] Ivanov AV,Smirnova OA,Kochetkov SN.HCV and oxidative stress in the liver.Viruses2013;5:439-69 PMCID:PMC3640510

[103] Muriel P.Role of free radicals in liver diseases.Hepatol Int2009;3:526-36 PMCID:PMC2790593

[104] Farinati F,De Maria N.Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis.J Hepatol1995;22:449-56

[105] Koike K.Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways.J Gastroenterol Hepatol2007;22 Suppl 1:S108-11

[106] Ivanov AV,Ivanova ON,Kochetkov SN.Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells.PLoS One2011;6:e24957 PMCID:PMC3172309

[107] Ming-Ju H,Tzy-Yen C.Hepatitis C virus E2 protein induce reactive oxygen species (ROS)-related fibrogenesis in the HSC-T6 hepatic stellate cell line.J Cell Biochem2011;112:233-43

[108] Li S,Yu X.Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-kappaB activation.Virology2009;391:257-64

[109] Yen HH,Lin TT,Soon MS.Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C.World J Gastroenterol2012;18:5084-9 PMCID:PMC3460336

[110] Piccoli C,Ripoli M.HCV infection induces mitochondrial bioenergetic unbalance: causes and effects.Biochim Biophys Acta2009;1787:539-46

[111] Piccoli C,D’Aprile A.Mitochondrial dysfunction in hepatitis C virus infection.Biochim Biophys Acta2006;1757:1429-37

[112] Qadri I,Capasso JM.Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1.Biochem J2004;378:919-28 PMCID:PMC1224028

[113] Nagaraju GP,Kasa P,El-Rayes BF.Epigenetics in hepatocellular carcinoma.Semin Cancer Biol2022;86:622-32

[114] Braghini MR,Romito I.Epigenetic remodelling in human hepatocellular carcinoma.J Exp Clin Cancer Res2022;41:107 PMCID:PMC8943959

[115] Man S,Yan M,Ma L.Treatment for liver cancer: from sorafenib to natural products.Eur J Med Chem2021;224:113690

[116] Shigekawa Y,Ueno M.Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma.Oncotarget2018;9:34320-35 PMCID:PMC6188148

[117] Zhou P,Zhou YJ.Proportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patients.World J Gastroenterol2015;21:6665-74 PMCID:PMC4458777

[118] Glozak MA.Acetylation/deacetylation modulates the stability of DNA replication licensing factor Cdt1.J Biol Chem2009;284:11446-53 PMCID:PMC2670150

[119] Plissonnier ML,Levrero M.Non-coding RNAs and hepatitis C virus-induced hepatocellular carcinoma.Viruses2018;10:591 PMCID:PMC6265700

[120] Diaz G,Tice A.Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.Int J Cancer2013;133:816-24 PMCID:PMC3830961

[121] Murakami Y,Saigo K.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.Oncogene2006;25:2537-45

[122] Pezzuto F,Buonaguro FM.The role of circulating free DNA and MicroRNA in non-invasive diagnosis of HBV- and HCV-Related hepatocellular carcinoma.Int J Mol Sci2018;19:1007 PMCID:PMC5979406

[123] Tanaka A,Kurihara H.Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.World J Gastroenterol2007;13:5180-7 PMCID:PMC4171299

[124] Ramesh S.Hepatitis C and nonalcoholic fatty liver disease.Semin Liver Dis2004;24:399-413

[125] Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C.Gastroenterol Rep2016;4:24-9 PMCID:PMC4760068

[126] Asselah T,Marcellin P.Steatosis in chronic hepatitis C: why does it really matter?.Gut2006;55:123-30 PMCID:PMC1856395

[127] Koike K.Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection.J Gastroenterol2009;44 Suppl 19:82-8

[128] Saad Y,Nassar Y,Said M.A polymorphism in the microsomal triglyceride transfer protein can predict the response to antiviral therapy in Egyptian patients with chronic hepatitis C virus genotype 4 infection.Gut Liver2014;8:655-61 PMCID:PMC4215453

[129] Hino K,Nishina S.Mitochondrial reactive oxygen species as a mystery voice in hepatitis C.Hepatol Res2014;44:123-32

[130] Bose SK,Meyer K,Ray R.Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance.J Virol2012;86:6315-22 PMCID:PMC3372214

[131] Deng L,Ogawa W.Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway.J Virol2011;85:8556-68 PMCID:PMC3165828

[132] Loftus LV,Pienta KJ.Interplay between cell death and cell proliferation reveals new strategies for cancer therapy.Int J Mol Sci2022;23:4723 PMCID:PMC9105727

[133] Tavakolian S,Faghihloo E.Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers.Infect Agent Cancer2020;15:27 PMCID:PMC7195796

[134] Gutierrez-Chamorro L,Ezeonwumelu IJ,Ballana E.Cyclin-dependent kinases as emerging targets for developing novel antiviral therapeutics.Trends Microbiol2021;29:836-48

[135] Otsuka M,Lan K.Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability.J Biol Chem2000;275:34122-30

[136] Wang F,Takamatsu M.Complex formation between hepatitis C virus core protein and p21Waf1/Cip1/Sdi1.Biochem Biophys Res Commun2000;273:479-84

[137] Kwun HJ.Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene.J Viral Hepat2003;10:249-55

[138] Munakata T,Liang Y,Lemon SM.Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase.Proc Natl Acad Sci USA2005;102:18159-64 PMCID:PMC1307512

[139] Masalova OV,Solyev PN.Modulation of cell death pathways by hepatitis C virus proteins in Huh7.5 hepatoma cells.Int J Mol Sci2017;18:2346 PMCID:PMC5713315

[140] Qian S,Yang W,Yang Y.The role of BCL-2 family proteins in regulating apoptosis and cancer therapy.Front Oncol2022;12:985363 PMCID:PMC9597512

[141] Otsuka M,Taniguchi H.Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression.Virology2002;296:84-93

[142] Vescovo T,Vitagliano G,Piacentini M.Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma.Clin Microbiol Infect2016;22:853-61

[143] Cheng D,Yang G.Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival.Liver Int2015;35:1682-91

[144] Easterbrook PJ,Sands A.Diagnosis of viral hepatitis.Curr Opin HIV AIDS2017;12:302-14 PMCID:PMC5389598

[145] Hong YS,Ryu S.Hepatitis B and C virus infection and diabetes mellitus: a cohort study.Sci Rep2017;7:4606 PMCID:PMC5496892

[146] Bailey CJ.Metformin: historical overview.Diabetologia2017;60:1566-76

[147] Vallianou NG,Kazazis C.Metformin and cancer.Rev Diabet Stud2013;10:228-35 PMCID:PMC4160009

[148] Schutte SC.A tissue-engineered human endometrial stroma that responds to cues for secretory differentiation, decidualization, and menstruation.Fertil Steril2012;97:997-1003 PMCID:PMC3319234

[149] Miyoshi H,Iwama H.Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo.Int J Oncol2014;45:322-32

[150] Zhang X,Shang Y.Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1.J Cancer2020;11:479-87 PMCID:PMC6930432

[151] Kamarudin MNA,Zhou JR.Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects.J Exp Clin Cancer Res2019;38:491 PMCID:PMC6909457

[152] Chen J.MYBL2 is targeted by miR-143-3p and regulates breast cancer cell proliferation and apoptosis.Oncol Res2018;26:913-22 PMCID:PMC7844795

[153] Casadei Gardini A,De Matteis S.Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale.Eur J Cancer2017;86:106-14

[154] Qu Z,Liao M,Zhao J.In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma.Hepatol Res2012;42:922-33

[155] Moon AM,Tapper EB.Contemporary epidemiology of chronic liver disease and cirrhosis.Clin Gastroenterol Hepatol2020;18:2650-66 PMCID:PMC7007353

[156] Rich NE.Changing epidemiology of hepatocellular carcinoma within the United States and worldwide.Surg Oncol Clin N Am2024;33:1-12

[157] Garuti F,Avanzato F.The changing scenario of hepatocellular carcinoma in Italy: an update.Liver Int2021;41:585-97

[158] Viollet B,Sanz Garcia N,Foretz M.Cellular and molecular mechanisms of metformin: an overview.Clin Sci2012;122:253-70 PMCID:PMC3398862

[159] Krishan S,Sahni S.Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation.Mol Pharmacol2015;87:363-77

[160] Oo YH.Regulatory T-cell directed therapies in liver diseases.J Hepatol2013;59:1127-34

[161] Fontenot JD,Rudensky AY.Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.Nat Immunol2003;4:330-6

[162] Zheng MH,Braddock M.CD4⁺ CD25⁺ regulatory T cells: a therapeutic target for liver diseases.Expert Opin Ther Targets2008;12:313-26

[163] Li TY,Zhou G.Immune suppression in chronic hepatitis B infection associated liver disease: a review.World J Gastroenterol2019;25:3527-37 PMCID:PMC6658392

[164] Sugimoto K,Stadanlick J,Alter HJ.Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection.Hepatology2003;38:1437-48

[165] Granito A,Lalanne C.Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells in the immune microenvironment.World J Gastroenterol2021;27:2994-3009 PMCID:PMC8192285

[166] Takahashi A,Yamanaka A.Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis.Cancer Cell Int2014;14:53 PMCID:PMC4070401

[167] Gao C,Zhang H,Li XO.Metformin induces autophagy via the AMPK-mTOR signaling pathway in human hepatocellular carcinoma cells.Cancer Manag Res2020;12:5803-11 PMCID:PMC7371564

[168] Graham GG,Arora M.Clinical pharmacokinetics of metformin.Clin Pharmacokinet2011;50:81-98

[169] Choi J.Statins and metformin for chemoprevention of hepatocellular carcinoma.Clin Liver Dis2016;8:48-52 PMCID:PMC6490194

[170] Nkontchou G,Aout M.Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.J Clin Endocrinol Metab2011;96:2601-8

[171] Del Campo JA,Gil-Gómez A.Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.PLoS One2018;13:e0191805 PMCID:PMC5791999

[172] Xie W,Sheng H.Metformin induces growth inhibition and cell cycle arrest by upregulating MicroRNA34a in renal cancer cells.Med Sci Monit2017;23:29-37 PMCID:PMC5226302

[173] Li JH,Xie XY.Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis.Am J Cancer Res2016;6:2109

[174] Jung WJ,Choi WJ.Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients.Sci Rep2022;12:14482 PMCID:PMC9411109

[175] Zhou X,Yi G.Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma.Oncotarget2016;7:873-84 PMCID:PMC4808039

[176] Chen ML,Zhang JB.Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.Front Endocrinol2022;13:996228 PMCID:PMC9520252

[177] Kudo M,Izumi N.Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.Oncology2014;87 Suppl 1:22-31

[178] Abdelmonsif DA,El-Hadidy WF.Targeting AMPK, mTOR and β-catenin by combined metformin and aspirin therapy in HCC: an appraisal in egyptian HCC patients.Mol Diagn Ther2018;22:115-27

[179] Ielasi L,Tonnini M.Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: a tale of multiple confounders.Cancers2021;13:6376 PMCID:PMC8699252

[180] Pasche B,Pennison M.Prevention and treatment of cancer with aspirin: where do we stand?.Semin Oncol2014;41:397-401 PMCID:PMC4099965

[181] Kasmari AJ,Liu G,McGarrity T.Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome.Am J Med2017;130:746.e1-7

[182] Lai SW,Liao KF,Lin CC.Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.Am J Gastroenterol2012;107:46-52

[183] Chen CI,Fang YA.Cancer risk in HBV patients with statin and metformin use: a population-based cohort study.Medicine2015;94:e462 PMCID:PMC4602747

[184] Vilar-Gomez E,Desai AP.Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.Aliment Pharmacol Ther2019;50:317-28

[185] Tsai PC,Hung CH.Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.J Hepatol2023;78:281-92

[186] Shen C,Shen B.Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.Oncotarget2016;7:62647-56 PMCID:PMC5308754

[187] Luo Z,Guo W.AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.Future Oncol2010;6:457-70 PMCID:PMC2854547

[188] Jiang X,Teng S,Wang D.The role of AMP-activated protein kinase as a potential target of treatment of hepatocellular carcinoma.Cancers2019;11:647 PMCID:PMC6562911

[189] Nakashima K,Chihara K,Sada K.Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways.Microbiol Immunol2011;55:774-82

[190] Foretz M,Leclerc J.Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.J Clin Invest2010;120:2355-69 PMCID:PMC2898585

[191] Zheng L,Wu F.Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.Clin Cancer Res2013;19:5372-80

[192] Hu JW,Zhang J.Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of hepatocellular carcinoma.J Cancer2020;11:6437-44 PMCID:PMC7532521

[193] Ling S,Fan N.Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.Int J Oncol2017;50:297-309

[194] Sun R,Ma C.Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway.Cancer Med2020;9:1141-51 PMCID:PMC6997051

[195] Perkins ND.NF-κB: tumor promoter or suppressor?.Trends Cell Biol2004;14:64-9

[196] Sultuybek G, Soydas T, Yenmis G. NF-κB as the mediator of metformin’s effect on ageing and ageing-related diseases.Clin Exp Pharmacol Physiol2019;46:413-22

[197] Luedde T.NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2011;8:108-18 PMCID:PMC3295539

[198] He G.NF-κB and STAT3 - key players in liver inflammation and cancer.Cell Res2011;21:159-68 PMCID:PMC3193410

[199] Xu J,Wu G,Li M.IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma.Front Oncol2021;11:760971 PMCID:PMC8714735

[200] Lipton JO.The neurology of mTOR.Neuron2014;84:275-91 PMCID:PMC4223653

[201] Hay N.Upstream and downstream of mTOR.Genes Dev2004;18:1926-45

[202] Wipperman MF,Gotto AM Jr.Mammalian target of rapamycin: a metabolic rheostat for regulating adipose tissue function and cardiovascular health.Am J Pathol2019;189:492-501 PMCID:PMC6412382

[203] Ferrín G,Amado V,De la Mata M.Activation of mTOR signaling pathway in hepatocellular carcinoma.Int J Mol Sci2020;21:1266 PMCID:PMC7072933

[204] Wang Z,Jin H.mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.Biomed Res Int2014;2014:735672 PMCID:PMC3996896

[205] Fischer R,Blum HE.Hepatitis C virus infection and apoptosis.World J Gastroenterol2007;13:4865-72 PMCID:PMC4611765

[206] Lin S.Interference of apoptosis by hepatitis B virus.Viruses2017;9:230 PMCID:PMC5580487

[207] Yi Y,Yi J.Role of p53 family proteins in metformin anti-cancer activities.J Cancer2019;10:2434-42 PMCID:PMC6584340

[208] Lu G,Shang J,Chen C.The effects of metformin on autophagy.Biomed Pharmacother2021;137:111286

[209] Lin D,Osman H.Additional inhibition of Wnt/β-catenin signaling by metformin in DAA Treatments as a novel therapeutic strategy for HCV-infected patients.Cells2021;10:790 PMCID:PMC8065725

[210] Cai W,Song L.IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K/akt and RAS/raf/ERK signaling pathways.BMC Cancer2023;23:87 PMCID:PMC9875405

[211] Vacante F,Montesano A,Luzi L.Metformin counteracts HCC progression and metastasis enhancing KLF6/p21 expression and downregulating the IGF axis.Int J Endocrinol2019;2019:7570146 PMCID:PMC6350585

[212] Geh D,Reeves HL.NAFLD-associated HCC: progress and opportunities.J Hepatocell Carcinoma2021;8:223-39 PMCID:PMC8041650

[213] Adinolfi LE,Guerrera B.NAFLD and NASH in HCV infection: prevalence and significance in hepatic and extrahepatic manifestations.Int J Mol Sci2016;17:803 PMCID:PMC4926337

[214] Wang B,Fang H.Hepatitis B virus infection is not associated with fatty liver disease: evidence from a cohort study and functional analysis.Mol Med Rep2019;19:320-6 PMCID:PMC6297757

[215] Zhang Y,Xiao H.Metformin actions on the liver: protection mechanisms emerging in hepatocytes and immune cells against NASH-related HCC.Int J Mol Sci2021;22:5016 PMCID:PMC8126028

[216] Zhao D,Geng W.Metformin suppresses interleukin-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway.J Gastroenterol Hepatol2021;36:3469-76